OMARINI, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.135
EU - Europa 4.458
AS - Asia 1.726
SA - Sud America 205
AF - Africa 48
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 10
Totale 12.609
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.084
IT - Italia 1.187
GB - Regno Unito 862
IE - Irlanda 827
SG - Singapore 513
CN - Cina 403
DE - Germania 387
SE - Svezia 354
HK - Hong Kong 284
RU - Federazione Russa 188
BR - Brasile 180
FR - Francia 152
ID - Indonesia 110
FI - Finlandia 100
UA - Ucraina 96
TR - Turchia 72
IN - India 70
BG - Bulgaria 59
VN - Vietnam 47
CA - Canada 40
TW - Taiwan 37
JP - Giappone 36
LT - Lituania 36
NL - Olanda 33
IQ - Iraq 32
BE - Belgio 28
AU - Australia 24
CZ - Repubblica Ceca 24
EG - Egitto 24
MY - Malesia 23
IR - Iran 19
AT - Austria 17
ES - Italia 14
PL - Polonia 13
MD - Moldavia 12
RO - Romania 12
CH - Svizzera 11
EU - Europa 10
KR - Corea 9
PH - Filippine 9
PK - Pakistan 9
CL - Cile 8
AR - Argentina 7
BD - Bangladesh 7
GR - Grecia 6
HU - Ungheria 6
GH - Ghana 5
MT - Malta 5
AL - Albania 4
AZ - Azerbaigian 4
CR - Costa Rica 4
MA - Marocco 4
NO - Norvegia 4
SY - Repubblica araba siriana 4
UZ - Uzbekistan 4
CO - Colombia 3
DO - Repubblica Dominicana 3
IL - Israele 3
IS - Islanda 3
KH - Cambogia 3
LV - Lettonia 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
PE - Perù 3
PT - Portogallo 3
SA - Arabia Saudita 3
TH - Thailandia 3
ZA - Sudafrica 3
CY - Cipro 2
DK - Danimarca 2
EC - Ecuador 2
HR - Croazia 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LK - Sri Lanka 2
MK - Macedonia 2
MX - Messico 2
NP - Nepal 2
RS - Serbia 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BO - Bolivia 1
CG - Congo 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
JM - Giamaica 1
JO - Giordania 1
LU - Lussemburgo 1
MC - Monaco 1
MO - Macao, regione amministrativa speciale della Cina 1
NI - Nicaragua 1
OM - Oman 1
PS - Palestinian Territory 1
QA - Qatar 1
Totale 12.605
Salva come PNG Salva come JPEG
Città #
Santa Clara 950
Dublin 823
Fairfield 636
Chandler 592
Ashburn 481
Southend 420
Singapore 348
Woodbridge 294
Houston 282
Hong Kong 269
Nyköping 259
Seattle 252
Wilmington 228
Ann Arbor 227
Dearborn 215
London 197
Cambridge 176
Jacksonville 143
Modena 130
New York 109
Jakarta 102
Beijing 97
Helsinki 84
Milan 74
San Diego 74
Moscow 71
Fremont 62
Princeton 60
Shanghai 59
Sofia 59
Rome 56
Bologna 55
Redwood City 52
Council Bluffs 44
Eugene 44
Dong Ket 41
Munich 39
Izmir 37
Frankfurt am Main 35
Bremen 33
Los Angeles 33
Enfield 32
Lauterbourg 30
Parma 27
San Giuliano Milanese 26
Falls Church 25
Portsmouth 24
Baghdad 23
Guangzhou 22
Asyut 21
Brussels 21
Chicago 20
Tokyo 20
Reggio Emilia 19
Nuremberg 16
Brno 15
Düsseldorf 15
Phoenix 15
Banqiao 14
Paris 14
Absecon 13
Boardman 13
Toronto 13
Chisinau 12
Des Moines 12
Nanjing 12
Norwalk 12
Ottawa 12
Palermo 12
São Paulo 12
Genoa 11
New Taipei 11
Padova 11
Sassuolo 11
Florence 10
Kunming 10
Bergamo 9
Amsterdam 8
Bengaluru 8
Caprarola 8
Castelvetrano 8
Dallas 8
Glasgow 8
Napoli 8
Turin 8
Istanbul 7
San Mateo 7
Santorso 7
Sydney 7
Venezia 7
Cardiff 6
Carpi 6
Changchun 6
Falkenstein 6
Forlì 6
Hefei 6
Madrid 6
Monza 6
Mumbai 6
Mykolayiv 6
Totale 8.996
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 444
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 314
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 296
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 283
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 266
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 257
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 253
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 250
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 244
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 239
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 235
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 234
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 230
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 229
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 228
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 227
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 223
Immune characterization of breast cancer metastases: prognostic implications. 222
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 220
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 212
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 212
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 211
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 209
PROFILO MUTAZIONALE DI TUMORI MAMMARI HER2 POSITIVI TRATTATI CON CHEMIOTERAPIA NEOADIUVANTE​ 200
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 199
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 196
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 192
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 190
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 183
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 182
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 181
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 179
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 177
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 171
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 169
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 167
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 167
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 164
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 162
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 161
Lapatinib and renal impairment: a case report 159
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 158
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 157
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. 152
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 150
The Role of Exosomes in Breast Cancer Diagnosis. 150
Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study. 149
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 148
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 144
Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC). 144
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 135
TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis 134
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 133
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. 130
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 127
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it! 127
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 126
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges 122
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 120
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 120
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis. 104
Next Generation Sequencing (NGS): a possible game changer in metastatic breast cancer 91
Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis 81
Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist 81
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affectclinical outcome of metastatic breast cancer patients 80
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 71
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. 68
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 68
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 60
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 58
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer (HR+/HER2- mBC): regulatory aspects and clinical impact in Europe 58
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 56
TDM-1 efficacy in trastuzumabpertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 48
Atezolizumab-Related Sarcoidosis-Like Reaction in Early Breast Cancer Patient: Know It To Diagnose It: A Case Report with Review of the Literature 44
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 43
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 36
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 35
Pneumonitis and pulmonary fibrosis associated with breast cancer treatments 31
EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project 31
Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer 24
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 18
Totale 12.749
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.819
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.819
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020204 0 0 0 0 0 0 0 0 0 75 80 49
2020/20211.591 149 100 75 125 183 129 70 180 102 195 124 159
2021/20221.368 77 147 117 58 51 110 63 71 131 126 251 166
2022/20232.647 191 266 146 186 174 202 47 156 960 50 168 101
2023/20241.429 75 65 102 138 175 130 160 211 54 64 102 153
2024/20253.144 141 53 127 268 814 592 319 257 410 163 0 0
Totale 12.749